| Abstract | This study demonstrates the potential of in vivo, whole body fluorescence imaging for pharmacokinetic studies. The distribution of a novel human anti-tumour antibody fragment, NovoMab-G2-scFv, labelled with a fluorescent dye (Cy5.5.18) was monitored in vivo. The NovoMab-G2-scFv–Cy5 complex was injected via the tail vein into nude mice bearing subcutaneous human melanoma tumour cells. The distribution of fluorescence NovoMab-G2-scFv–Cy5 was imaged non-invasively using a charge-coupled device (CCD) camera. Whole body fluorescence images were acquired 2, 6, 12, 24, 48 and 72 h post-injection. Fluorescence was detected at the tumour site following injection of NovoMab-G2-scFv–Cy5 but not following injection of a labelled irrelevant antibody fragment, demonstrating specific binding of the antibody–dye complex to the tumour. Fluorescence from the tumour site peaked 2 h post-injection and gradually declined, reaching a minimum 72 h post-injection. Fitting an exponential decay to fluorescence data extracted from images allowed the half-time of the antibody at the tumour site to be calculated, and a value of 7.7 h was obtained. Fluorescence was also apparent in the kidneys, indicating clearance of the NovoMab-G2-scFv through the kidneys. Again, fluorescence intensity decreased with time, reaching a minimum 72 h post-injection. Imaging of isolated organs (ex vivo) confirmed the presence of the antibody–dye complex in the tumours, kidneys and liver. No fluorescence was observed in the brain, heart, lungs or spleen, suggesting that these organs do not accumulate the NovoMab-G2-scFv–dye complex. |
|---|
